What is the optimal dose of finasteride for hair loss?

Scientific concepts / discoveries / nature phenomena in the subtitles

Finasteride for androgenetic alopecia (male pattern hair loss)

• Central question: optimal dose for hair loss treatment.
• Key mechanism: finasteride suppresses DHT (dihydrotestosterone) by inhibiting the enzyme 5α-reductase (which converts testosterone → DHT).
• DHT suppression is discussed at both:
  • Serum levels, and
  • Scalp levels (in one referenced study).

Dose–response relationships (efficacy vs dose)

A 1999 dose-ranging evidence base is used to argue:

• 0.01 mg/day: reduces DHT, but is ineffective for hair growth outcomes.
• 0.2 mg/day: appears to be the minimum effective dose for meaningful hair regrowth.
• 1 mg/day: works and is slightly better than 0.2 mg/day.
• 5 mg/day: provides no clinically meaningful added benefit over 1 mg/day (hair outcomes are “about equally effective”); suggests a plateau near 1 mg/day for therapeutic effect.

Hair growth outcome measures

Trial endpoints include:

• Hair counts
• Phototrichograms
• Patient self-assessments
• Investigator assessments
• Global photographic assessments

Testosterone rebound and potential downstream effects

• Finasteride increases testosterone levels (reported as ~18–19% across doses >0.2 mg/day) because less testosterone is converted into DHT.
• The video speculates that increased testosterone could raise estradiol via aromatization, which might contribute to sexual side effects (while noting the true cause is not established).

Mechanistic data vs outcome data

An emphasized example is that:

• 0.01 mg/day suppresses DHT but does not improve hair growth, supporting the idea that:
  • Lower DHT suppression isn’t sufficient, and
  • Clinical outcome (efficacy) matters more than mechanism alone.

Dosing frequency and pharmacodynamic persistence

• Claims:
  • Finasteride has a short half-life (hours),
  • but DHT-suppressing effects persist up to ~4 days, implying potential benefit from every-other-day dosing.
• A note is made that dermatology practice broadly corroborates this (described as general assertion rather than trial evidence in the subtitles).

Side effects and dose dependence (evidence discussion)

• Reported trial safety profiles are described as similar to placebo across studied doses.
• The video argues that:
  • efficacy trials can have smaller samples because many people respond,
  • side effects are rare, so detecting dose differences reliably requires very large samples (thousands).
• Preview claim: 5 mg likely has a higher side-effect profile than 1 mg (to be covered in a “next video”).

---

Methodology / study design elements (as described)

1999 scalp biopsy dose study (men with androgen alopecia)

• Design: oral finasteride dose-ranging.
• Doses tested: 5 mg/day down to 0.01 mg/day
• Measured outcomes:
  • Serum DHT
  • Scalp DHT
• Main inference:
  • ≥0.2 mg/day produces significant reductions in scalp + serum DHT
  • 0.05 mg/day may reduce scalp DHT with less serum impact
• Limitation mentioned: no follow-up clinical hair-growth studies at these lower doses.

1999 clinical hair-loss outcome trial (double-blind, placebo-controlled)

• Participants: men with Norwood III or IV androgenetic alopecia
• Arms: each with approximately ~110 subjects:
  • 5 mg
  • 1 mg
  • 0.2 mg
  • 0.01 mg
  • placebo
• Duration: 6–12 months
• Endpoints:
  • Hair counts (including phototrichograms)
  • Patient self-assessments
  • Investigator assessments
  • Global photographic assessments
  • Serum DHT and testosterone levels

---

Researchers / sources featured

• No specific researchers, authors, institutions, or journals are named in the subtitles.
• The subtitles cite:
  • a 1999 scalp biopsy study, and
  • a 1999 double-blind, placebo-controlled dose-ranging hair-growth study.
• FDA approval is referenced for the 1 mg/day hair-loss indication, but no individual FDA author is named.

Named persons: None.